• Patients with peripheral T-cell lymphoma (including but not limited to PTCL-NOS, angioimmunoblastic T-cell lymphoma, anaplastic large T-cell lymphoma). Patients with mycosis fungoides with large cell transformation with measurable disease are eligible.

• Disease status defined as refractory to or relapsed after ≥ 1 prior treatment lines.

• Patients irrespective of transplant eligibility status can be enrolled; however patients can be seen by SCT team in anticipation for SCT.

• Subjects with ALK+ ALCL should have been treated with, be ineligible for, or have refused chemotherapy and brentuximab prior to enrollment on the current study.

• Patients with a measurable disease, defined by a node or mass with the longest diameter ≥ 1.5cm.

∙ In order to be eligible for participation in this trial, the subject must:

• Be willing and able to provide written informed consent/assent for the trial.

• Be 18 years of age on day of signing informed consent.

• Patients with PTCL should have radiographically measurable disease \>/= 1.5cm.

• Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 12 weeks(84 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen.

• Have a performance status of 0, 1 or 2 on the ECOG Performance Scale.

• Demonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 14 days of treatment initiation.

• Table 1 Adequate Organ Function Laboratory Values System Laboratory Value

⁃ Hematological

⁃ Absolute neutrophil count (ANC) ≥ 1000 /mcL

⁃ Platelets ≥100,000 / mcL. If bone marrow is involved, platelets should be at least 50K and ANC 750 / mcL

⁃ Hemoglobin ≥ 8g/dL without transfusion or EPO dependency (within 7 days of assessment)

⁃ Renal

⁃ Serum creatinine OR Measured or calculateda creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR

‣ ≥60 mL/min for subject with creatinine levels \> 1.5 X institutional ULN

⁃ Hepatic

⁃ Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 ULN

⁃ AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR

‣ ≤ 5 X ULN for subjects with liver metastases

⁃ Albumin \> 2 mg/dL

⁃ Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants aCreatinine clearance should be calculated per institutional standard.

• Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

• Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the course of the study through 120 days after the last dose of study medication.

• Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

• Male subjects of childbearing potential (Section 5.7. .2 must agree to use an adequate method of contraception as outlined in Section 5.7. .2- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.

• Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

⁃ Relapsed/refractory Cutaneous T cell Lymphomas (CTCL) patients with transformed and aggressive T Cell with predominant lymph node involvement and those that are measurable by standard T Cell criterial. These patients require failure of at least one prior systemic therapy for the transformed lymphoma.